重組促促血紅細胞生長素市場：依藥物類型、依應用、依配銷通路、按地區

Recombinant Erythropoietin Market, By Drug Type, By Application, By Distribution Channel, By Geography

出版日期: 2023年11月08日 | 出版商:

Coherent Market Insights | 英文 170 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年，全球重組促血紅細胞生長素市場規模為70.1億美元，預計2030年將達到86.8億美元，2023年至2030年年複合成長率為3.1%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	70.1億美元
實績資料	2018-2021	預測期	2023-2030
預測期年複合成長率	3.10%	2030年市場規模預測	86.8億美元

圖 1. 重組促促血紅細胞生長素的全球市場佔有率(%)（按地區），2023 年

重組促促血紅細胞生長素是天然促促血紅細胞生長素的生物工程版本，它在腎臟中產生，以刺激紅血球的產生。這種重組促促血紅細胞生長素通常是在實驗室中使用基因改造細菌或哺乳動物細胞生產的。重組促促血紅細胞生長素主要用於治療貧血，特別是患有慢性腎臟病或接受癌症化療的患者。促血紅細胞生長素刺激骨髓產生更多的紅血球，增加血液的攜氧能力。

重組促促血紅細胞生長素(rEPO) 是一項突破性的醫學發展，徹底改變了貧血及相關疾病的治療。促血紅細胞生長素是腎臟自然產生的一種激素，可刺激骨髓中紅血球 (RBC) 的產生。重組DNA技術使得在實驗室生產合成促促血紅細胞生長素成為可能，rEPO就此誕生。這為治療貧血提供了一種非常有效的方法，特別是對於患有慢性腎臟病、癌症和某些遺傳性疾病的患者。透過給藥rEPO，醫療保健專業人員可以刺激紅血球生成，提高攜氧能力，並緩解疲勞和虛弱等貧血症狀。此外，rEPO 在減少輸血需求和改善患者生活品質方面已顯示出顯著的益處。重組促紅血球促血紅細胞生長素的廣泛普及徹底改變了貧血管理，並繼續在各個醫學領域發揮重要作用。

市場動態：

慢性慢性腎臟病（CKD）和癌症等慢性病盛行率的上升預計將在預測期內推動全球重組促促血紅細胞生長素製劑市場的成長。例如，根據出版商 John Wiley &Sons, Inc. 2023 年 1 月 12 日發布的資料，預計 2023 年美國將新增 1,958,310 例癌症病例，609,820 例癌症死亡。

然而，嚴格的監管要求、安全問題、副作用和報銷挑戰預計將阻礙預測期內全球重組促促血紅細胞生長素市場的成長。

本研究的主要特點

本報告對全球重組促促血紅細胞生長素市場進行了詳細分析，並列出了以2022年為基準年的預測期（2023-2030年）的市場規模和年複合成長率。
它還揭示了各個細分市場的潛在商機，並解釋了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
它根據公司亮點、產品系列、主要亮點、財務實績和策略等參數，介紹了全球重組促血紅細胞生長素市場的主要企業。
該報告的見解將使行銷人員和公司負責人能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出資訊的決策。
本研究報告針對該產業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
相關人員可以透過用於分析全球重組促促血紅細胞生長素市場的各種策略矩陣來促進他們的決策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 7.01 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	3.10%	2030 Value Projection:	US$ 8.68 Bn

Recombinant erythropoietin is a bioengineered version of a naturally occurring hormone, erythropoietin, which is produced by the kidneys to stimulate the production of red blood cells. This recombinant version is produced in a laboratory, typically using genetically modified bacteria or mammalian cells. Recombinant erythropoietin is used primarily to treat anemia, particularly in individuals with chronic kidney disease or undergoing chemotherapy for cancer. It works by stimulating the bone marrow to produce more red blood cells, thereby increasing the oxygen-carrying capacity of the blood.

Recombinant erythropoietin (rEPO) is a revolutionary medical development that has transformed the treatment of anemia and related conditions. Erythropoietin is a hormone naturally produced by the kidneys, stimulating the production of red blood cells (RBC) in the bone marrow. Recombinant DNA technology has made it possible to produce synthetic erythropoietin in the laboratory, resulting in the creation of rEPO. This has provided has provided a highly effective approach to managing anemia, particularly in patients with chronic kidney diseases, cancer, and certain genetic disorders. By administering rEPO, healthcare professionals can stimulate RBC production, improve oxygen-carrying capacity, and alleviating symptoms of anemia, such as fatigue and weakness. Furthermore, rEPO has demonstrated significant benefits in reducing the need for blood transfusions and enhancing quality of life for patients. The widespread adoption of recombinant erythropoietin has revolutionized anemia management and continues to play a crucial role in various medical fields.

Market Dynamics:

The rising prevalence of chronic diseases such as chronic kidney disease (ckd) and cancer is anticipated to drive growth of the global recombinant erythropoietin market over the forecast period. For instance, according to data published on January 12, 2023, by John Wiley & Sons, Inc., a publishing company, in 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the U.S.

However, stringent regulatory requirements, safety concerns, side effects, and reimbursement challenges are expected to hamper growth of the global recombinant erythropoietin market over the forecast period.

Key features of the study:

This report provides in-depth analysis of the global recombinant erythropoietin market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global recombinant erythropoietin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Amgen Inc., Johnson & Johnson (Janssen Pharmaceuticals), Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, Biocon Limited, LG Chem Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Celltrion Inc., 3SBio Inc., BioSidus SA, Astellas Pharma Inc, and Lotus Pharmaceutical Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global recombinant erythropoietin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global recombinant erythropoietin market

Detailed Segmentation:

By Drug Type:
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others
By Application:
- Cancer
- Hematology
- Renal diseases
- Neurology
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Amgen Inc.
- Johnson & Johnson (Janssen Pharmaceuticals)
- Pfizer Inc.
- F. Hoffmann-La Roche AG
- Novartis AG
- Biocon Limited
- LG Chem Ltd.
- Intas Pharmaceuticals Ltd.
- Dr. Reddy's Laboratories Ltd.
- Celltrion Inc.
- 3SBio Inc.
- BioSidus SA
- Astellas Pharma Inc
- Lotus Pharmaceutical Co., Ltd

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Recombinant Erythropoietin, By Drug Type
- Market Recombinant Erythropoietin, By Application
- Market Recombinant Erythropoietin, By Distribution Channel
- Market Recombinant Erythropoietin, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Rising prevalence of chronic kidney disease (ckd)
- Restraints
Stringent Regulatory Requirements
- Opportunities
Emerging Markets
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Recombinant Erythropoietin Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Recombinant Erythropoietin Market , By Drug Type, 2018-2030, (US$ billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Epoetin-alfa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Epoetin-beta
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Darbepoetin-alfa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)

6. Recombinant Erythropoietin Market, By Application, 2018-2030, (US$ billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Hematology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Renal diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Neurology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)

7. Recombinant Erythropoietin Market , By Distribution Channel, 2018-2030, (US$ billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)

8. Recombinant Erythropoietin Market , By Region, 2018-2030, (US$ billion)

Introduction
- Market Share Analysis, By Country, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Country 2019-2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- 2018 - 2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018 - 2030, (US$ Bn)
North Africa
Central Africa
South Africa